Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Inventiva S.A. ADR (IVA)

Inventiva S.A. ADR (IVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,321
  • Shares Outstanding, K 52,477
  • Annual Sales, $ 25,070 K
  • Annual Income, $ -119,510 K
  • EBIT $ 0 M
  • EBITDA $ -108 M
  • 60-Month Beta 0.85
  • Price/Sales 6.52
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.56
  • Number of Estimates 1
  • High Estimate -0.56
  • Low Estimate -0.56
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.22 +5.86%
on 12/19/24
2.82 -16.67%
on 11/26/24
-0.39 (-14.23%)
since 11/20/24
3-Month
1.53 +53.59%
on 09/26/24
2.85 -17.54%
on 11/08/24
+0.30 (+14.63%)
since 09/20/24
52-Week
1.53 +53.59%
on 09/26/24
4.75 -50.53%
on 01/03/24
-1.85 (-44.05%)
since 12/20/23

Most Recent Stories

More News
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 1.0400 (-48.00%)
GLMD : 3.05 (-0.65%)
VKTX : 42.25 (+1.83%)
ETNB : 7.94 (+12.94%)
IVA : 2.35 (-0.84%)
SGMT : 4.95 (-2.37%)
TERN : 5.86 (-3.14%)
NVO : 85.00 (-17.83%)
IQV : 197.27 (+3.00%)
MDGL : 308.44 (+5.12%)
Inventiva Reports 2022 First-Half Financial Information¹

Cash position2 at €87.2 m as of June 30, 2022Revenues of €0.1 m in H1 2022Inventiva entered into a finance loan and a warrant agreement for up to €50...

IVA : 2.35 (-0.84%)
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical...

IVA : 2.35 (-0.84%)
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin...

IVA : 2.35 (-0.84%)
Update on Inventiva's cash position and on the finance documentation with the European Investment Bank

Inventiva successfully raised approximately €14.6 million through a combination of its ATM Program for €9.3 million and new State-backed bank financing for...

IVA : 2.35 (-0.84%)
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022

Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven...

IVA : 2.35 (-0.84%)
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022

Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH...

IVA : 2.35 (-0.84%)
Inventiva joins the Euronext Tech Leaders segment

Inventiva has been selected for inclusion in Euronext’s new segment alongside more than 100 high-growth and Tech-driven European companiesInternational...

IVA : 2.35 (-0.84%)
Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association

Daix (France), Long Island City (New York, United States), June 3, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical...

IVA : 2.35 (-0.84%)
Inventiva announces participation at several investors conferences in May and June 2022

Daix (France), Long Island City (New York, United States), May 23, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage...

IVA : 2.35 (-0.84%)

Business Summary

Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Inventiva S.A. is based in Daix, France.

See More

Key Turning Points

3rd Resistance Point 2.44
2nd Resistance Point 2.39
1st Resistance Point 2.37
Last Price 2.35
1st Support Level 2.31
2nd Support Level 2.26
3rd Support Level 2.24

See More

52-Week High 4.75
Fibonacci 61.8% 3.52
Fibonacci 50% 3.14
Fibonacci 38.2% 2.76
Last Price 2.35
52-Week Low 1.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar